Form 4: Edwards Lifesciences CVP Reports Stock Transactions

Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences Corp, reported the acquisition of 6,410 restricted stock units and the disposition of 650 shares for tax purposes.

Summary

• Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences Corp (EW), reported changes in his beneficial ownership.
• On September 11, 2025, Markowitz acquired 6,410 shares of Common Stock through a restricted stock unit (RSU) grant.
• These RSUs were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.
• The RSUs are scheduled to vest and become exercisable commencing one year after the grant date in four equal annual installments.
• On September 14, 2025, Markowitz disposed of 650 shares of Common Stock at a price of $77.57 per share, likely for tax withholding related to RSU vesting or exercise.
• Following these transactions, Markowitz beneficially owns 18,145.8708 shares of Common Stock directly.
• The filing also notes the inclusion of quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive sign of long-term incentive alignment. The subsequent disposition of shares is a standard practice for tax withholding and does not indicate a negative sentiment towards the company.

Positives

• Grant of 6,410 restricted stock units to CVP, JAPAC Wayne Markowitz, aligning executive interests with long-term company performance.
• Participation in the company's Long-Term Stock Incentive Compensation Program indicates a structured approach to executive retention and motivation.

Negatives

• Disposition of 650 shares at $77.57 per share, which reduces the executive's direct holdings, although this is a common practice for tax withholding on RSU vesting.

Risks

• NA

Future Outlook

The 6,410 restricted stock units granted on September 11, 2025, are scheduled to vest and become exercisable in four equal annual installments, commencing one year after the grant date.

Management Comments

• The filing reflects changes in beneficial ownership only and does not identify other securities of the Issuer beneficially owned by the Reporting Person.
• The Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

Industry Context

Executive compensation packages often include equity components like restricted stock units (RSUs) to align management incentives with shareholder value creation. The disposition of shares for tax withholding is a standard practice upon RSU vesting or exercise in public companies.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the executive's interests with long-term shareholder value. The disposition for tax purposes is a routine event and does not significantly impact overall share structure.
• Employees: The mention of the Employee Stock Purchase Plan indicates broader employee participation in equity ownership.

Next Steps

• The restricted stock units will begin vesting one year after the grant date (September 11, 2025) in four equal annual installments.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, insider transaction, restricted stock units, RSU, executive compensation, stock grant, beneficial ownership, CVP, JAPAC